{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001840","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.670319+00:00","generated_at":"2026-06-05T12:34:38.184143+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Virios Therapeutics cuts cash compensation 10%; grants stock options to officers and directors","bullets":["Board approved 10% salary reduction for all employees including executive officers, effective March 1, 2024.","Non-employee director cash compensation also reduced by 10%.","Stock options granted to executive officers and directors: CEO Greg Duncan receives 138,835 options; total 410,570 options across 10 recipients.","Options have exercise price of $0.357/share and vest on February 26, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001840","json":"https://secwatch.observer/filing/0001558370-24-001840.json","markdown":"https://secwatch.observer/filing/0001558370-24-001840.md","text":"https://secwatch.observer/filing/0001558370-24-001840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024001840/0001558370-24-001840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024001840/tmb-20240226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:34:38.184143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}